- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00746733
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
June 8, 2021 updated by: Shire
A Phase I, Open-Label, Randomized, Four Period Crossover Drug Interaction Study to Evaluate the Pharmacokinetic Profiles of VYVANSE™ and ADDERALL XR When Each is Administered Alone and in Combination With the Proton Pump Inhibitor Prilosec OTC™ in Healthy Adult Volunteers
The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how much of the drug is absorbed into the body.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Clinical Pharmacology of Miami, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy volunteers, age 18 to 45 inclusive at the time of consent.
- Male, or non-pregnant, non-lactating female
- Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening, and a negative urine pregnancy test on Day -1 after checking into the clinic the day before the first dose of investigational product.
- Body Mass Index (BMI) between 20.0 and 30.0 kg/m² inclusive. This inclusion criterion will only be assessed at the first screening visit.
- Satisfactory medical assessment with no significant or relevant abnormality in medical history, physical examination (PE), vital signs and laboratory evaluation
- Normal or clinically insignificant Screening ECG findings as assessed by the Investigator.
- Ability to swallow investigational products.
Exclusion Criteria:
- Current or recurrent disease that could affect the action, absorption or disposition of the investigational products, or could affect clinical or laboratory assessments.
- Current or relevant previous history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational products or study procedures.
- Significant illness, as judged by the Investigator, within 2 weeks of the first dose of investigational product.
- History of significant anxiety, tension or agitation as assessed by the Investigator.
- History of or current diagnosis of glaucoma.
- History of a seizure disorder (other than infantile febrile seizures), any tic disorder or a current diagnosis and/or known family history of Tourette's Disorder.
- History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, transient ischemic attack or stroke or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
- History of controlled or uncontrolled hypertension or a resting sitting systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg.
- Known family history of sudden cardiac death or ventricular arrhythmia.
- Currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently demonstrating suicidal ideation.
- Current use of any medication (including prescription, over the counter [OTC], herbal or homeopathic preparations) with the exception of hormonal replacement therapy or hormonal contraceptives (Current use is defined as use within 14 days of first dose of investigational product).
- Use of any medication known to inhibit or induce the CYP450 enzymes responsible for the metabolism of the investigational products within 14 days of first dose of investigational product.
- Known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds or any of the stated ingredients.
- History of alcohol or other substance abuse within the last year.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vyvanse (LDX)
|
50mg capsule
|
Experimental: Adderall XR (AXR)
|
20mg capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
|
0 through 96 hours after dosing
|
Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
|
0 through 96 hours after dosing
|
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
|
0 through 96 hours after dosing
|
Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
|
0 through 96 hours after dosing
|
Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
|
0 through 96 hours after dosing
|
Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
|
0 through 96 hours after dosing
|
AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
0 through 96 hours after dosing
|
|
T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
|
0 through 96 hours after dosing
|
Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
Total amphetamine is the d- and l-amphetamines.
|
0 through 96 hours after dosing
|
Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
Total amphetamine is the d- and l-amphetamines.
|
0 through 96 hours after dosing
|
AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
Total amphetamine is the d- and l-amphetamines.
|
0 through 96 hours after dosing
|
T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: 0 through 96 hours after dosing
|
Total amphetamine is the d- and l-amphetamines.
|
0 through 96 hours after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.
Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
|
Question 2: How much do you like the effects you are feeling now?
Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot).
The higher the score the stronger the subjective experience.
This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.
|
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
|
DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC
Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
|
Question 1: How much do you feel the drug now?
Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot).
The higher the score the stronger the subjective experience.
This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.
|
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
|
DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC
Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
|
Question 3: Do you dislike the drug effect you are feeling now?
Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot).
The higher the score the stronger the subjective experience.
This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.
|
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
|
Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
|
Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
|
|
Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
|
Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
|
|
Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
|
Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
|
|
Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time Frame: Pre-dose, 2 and 8 hours after dosing
|
QTcF is the QT interval using Fridericia's correction formula.
QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval).
The QT interval has to be corrected in order to aid interpretation.
|
Pre-dose, 2 and 8 hours after dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Haffey MB, Buckwalter M, Zhang P, Homolka R, Martin P, Lasseter KC, Ermer JC. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009 Sep;121(5):11-9. doi: 10.3810/pgm.2009.09.2048.
- Wigal T, Brams M, Gasior M, Gao J, Giblin J. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med. 2011 Mar;123(2):169-76. doi: 10.3810/pgm.2011.03.2275.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 8, 2008
Primary Completion (Actual)
October 26, 2008
Study Completion (Actual)
October 26, 2008
Study Registration Dates
First Submitted
September 2, 2008
First Submitted That Met QC Criteria
September 3, 2008
First Posted (Estimate)
September 4, 2008
Study Record Updates
Last Update Posted (Actual)
June 14, 2021
Last Update Submitted That Met QC Criteria
June 8, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Lisdexamfetamine Dimesylate
- Amphetamine
- Adderall
Other Study ID Numbers
- SPD489-113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Lisdexamfetamine Dimesylate
-
ShireCompletedMajor Depressive DisorderUnited States, Chile, Australia, Argentina, United Kingdom
-
ShireCompletedSchizophrenia and Predominant Negative SymptomsUnited States
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
Gregory FabianoCompletedEfficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHDAttention Deficit Disorder With HyperactivityUnited States
-
ShireCompletedAttention-Deficit/Hyperactivity DisorderUnited States
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)Germany, Italy, Poland, Spain, Romania, Belgium, Hungary, Netherlands, Sweden, United Kingdom
-
ShireCompletedBinge Eating DisorderUnited States
-
ShireCompletedBinge Eating DisorderSpain, United States, Germany
-
Aaron KeshenNova Scotia Health AuthorityTerminated
-
Clinical Study Centers, LLCShireCompletedSleep | Attention Deficit Hyperactivity DisorderUnited States